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Abstract: Primary lung cancer remains the leading cause of cancer death worldwide. Promoter hypermethyla-
tion is a major inactivation mechanism of tumor-related genes, and increasingly appears to play an important
role in carcinogenesis. In the present study, we used quantitative methylation-specific PCR (Q-MSP) assays to
analyze promoter hypermethylation of nine genes in a large cohort of well-characterized non-small cell lung
cancer (NSCLC) and explore their associations with the clinicopathological features of tumor. We found that
there were significant differences in methylation levels for six of nine gene promoters between cancerous and
noncancerous lung tissues. More importantly, with 100% diagnostic specificity, high sensitivity, ranging from
44.9% to 84.1%, was found for each of the nine genes. Interestingly, promoter hypermethylation of most genes
was closely associated with histologic type, which was more frequent in squamous cell carcinomas (SCC) than in
adenocarcinomas (ADC). In addition, highly frequent concomitant methylation of multiple genes was found in
NSCLC, particularly in SCC. Our data showed that multiple genes were aberrantly methylated in lung tumori-
genesis, and that they were closely associated with certain clinicopathological features of NSCLC, particularly of
the histologic type, suggesting that these hypermethylated genes could be potential biomarkers in early detec-
tion of NSCLC in high-risk individuals, as well as in evaluating the prognosis of NSCLC patients. (Folia His-
tochemica et Cytobiologica 2011, Vol. 49, No. 1, 132–141)
Key words: DNA methylation, multiple genes, quantitative methylation-specific PCR (Q-MSP), non-small cell
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Introduction
Worldwide, lung cancer kills more than one million
people each year, and as the leading cause of death
in men, and the second leading cause in women, it is
a major health problem [1, 2]. Lung cancer is clinical-
ly classified into two major histological categories:
small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC). The former is the most aggressive
subtype, accounting for 10–15% of all cases. NCLSC
accounts for approximately 85–90% of lung cancers
[2]. Despite surgery, approximately 30–40% of pa-
tients with NSCLC who have discrete lesions and his-
tologically negative lymph nodes die of recurrent dise-
ase [3]. One reason for this problem is that this dise-
ase has proven difficult to diagnose early and treat
successfully. In fact, many imaging and cytology-based
strategies have been employed to achieve early de-
tection of lung cancer and identified high-risk indi-
viduals. Although some of these strategies are indeed
sensitive , none has been demonstrated to reduce lung
cancer mortality. Fortunately, specific molecular
markers would provide an alternative approach to
complement imaging techniques for the early diag-
nosis of lung cancer. Among them, DNA methyla-
tion has emerged as a highly promising biomarker,
and it is being actively studied in multiple cancers.
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Hypermethylation of gene promoter is an impor-
tant mechanism of gene inactivation and acts as an
alternative to mutational events, such as gene muta-
tions and intragenic deletions, in oncogenesis [4, 5].
Hypermethylation of gene promoter is the earliest and
commonest molecular event in human cancers, inclu-
ding NSCLC [6, 7], indicating that loss of gene trans-
cription mediated by methylation events is recognized
now as a crucial component in the initiation and pro-
gression of lung cancer. Taken together, hypermeth-
ylation of gene promoter may be an important biom-
arker for the early detection of lung cancer.
In the present study, we determined the DNA me-
thylation profiles of nine genes using quantitative me-
thylation-specific PCR (Q-MSP) in a cohort of clini-
cally well-characterized NSCLC samples. The selec-
ted genes play important roles in T- and B-cell regula-
tion in certain malignancies (CALCA), cell adhesion
and/or invasion and/or metastasis (CDH1), apoptosis
(DAPK1), development (EVX2 and IRX2), cell pro-
liferation and/or differentiation (PAX6, RARb, and
TIMP3), and cell cycle control (RASSF1A).
The aim of this study was to identify a panel of
genes that differentiate cancerous tissues from non-
cancerous tissues as excellent biomarkers for early
detection and prognostic evaluation of lung cancer,
and explore their associations with known or suspec-
ted cancer risk factors.
Material and methods
Clinical samples
With institutional approval, a series of 96 paraffin-em-
bedded primary NSCLC samples and 15 noncancerous
lung samples were randomly selected at the First Affi-
liated Hospital of China Medical University, People’s
Republic of China. None of these patients had received
chemotherapy or radiotherapy before the surgery. In-
formed consent was obtained from each patient before
the surgery. The histopathological diagnosis and sub-
type classification of NSCLC samples were examined
and agreed upon by an experienced pathologist at the
Department of Pathology of the Hospital. As shown in
Table 1, the mean age of all NSCLC cases was 58.9 years.
Those aged > 60 years accounted for 42%. There were
more males than females (69% vs. 31%). Sixty-nine
percent of patients had a smoking history. Ninety per
cent of NSCLC cases had surgical stage I and II dise-
ase and 84% had tumors < 5 cm. By histology, 69%
were squamous cell carcinomas (SCC), the remaining
31% being adenocarcinomas (ADC). Cases with lymph
node metastasis, pleural indentation and invasion or
adhesion were 26/96 (27%), 21/96 (22%), and 31/96
(32%), respectively.
Table 1. Baseline patient and tumor characteristics
of NSCLC cases
Characteristics No. of patients (%)
Gender
Male 66 (68.8)
Female 30 (31.2)
Age (mean years ± SD) 58.9 ± 9.2
£ 60 56 (58.3)
> 60 40 (41.7)
Smoking history (pack-years)
0 30 (31.3)
1–39 35 (36.5)
≥ 40 31 (32.2)
Tumor size (mean cm ± SD) 3.9 ± 1.7
1–3 37 (38.5)
3–5 44 (45.8)
> 5 15 (15.7)
Histologic type
Adenocarcinoma 30 (31.3)
     Bronchoalveolar cell (BAC) 6 (6.3)
     Adenocarcinoma (non-BAC) 24 (25)
Squamous 66 (68.7)
Histologic stage
I 54 (56.3)
II 32 (33.3)
III 10 (10.4)
Lymph node metastasis
No 70 (72.9)
Yes 26 (27.1)
Pleural indentation
No 75 (78.1)
Yes 21 (21.9)
Invasion or adhesion
No 65 (67.7)
Yes 31 (32.3)
DNA isolation
Paraffin-embedded NSCLC samples were treated and
DNA was isolated as previously described [8]. Brief-
ly, after an eight-hour treatment at room tempera-
ture with xylene to remove paraffin, samples were
incubated with 1% sodium dodecyl sulfate (SDS) and
0.5 mg/ml proteinase K at 48°C for 48 hours to digest
tissues. A few mid-interval spiking aliquots of con-
centrated proteinase K facilitated digestion. DNA was
subsequently isolated by standard phenol-chloroform
extraction and ethanol precipitation.
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Sodium bisulfite treatment
Genomic DNA from the primary tumors and non-
cancerous lung samples was subjected to treatment
of sodium bisulfite, as described previously [9]. Brief-
ly, a final volume of 20 ml of H2O containing ~2 mg
genomic DNA, 10 mg salmon sperm DNA, and 0.3M
NaOH was incubated at 50°C for 20 minutes to de-
nature the DNA. The mixture was then incubated
for 2–3 hours at 70°C in 500 ml of a freshly prepared
solution containing 3M sodium bisulfite (Sigma, St.
Louis, MO, USA), and 10 mM hydroquinone (Sig-
ma, St. Louis, MO, USA). DNA was subsequently
recovered by a Wizard DNA Clean-Up System
(Promega Corp., Madison, WI, USA) following the
instructions of the manufacturer, followed by ethanol
precipitation, and re-suspension in 30 ml of deionized
H2O. After bisulfite treatment, all unmethylated cy-
tosine residues converted to uracil, whereas the
methylated cytosine residues remained unchanged.
Bisulfite-treated DNA samples were stored at –80°C
until use.
Quantitative methylation-specific PCR
(Q-MSP) assay
The methylation status was determined by the flu-
orescence-based quantitative PCR assay as de-
scribed previously [9]. Briefly, the Q-MSP assay was
carried out in triplicate for each sample in a final
reaction mixture of 20 ml containing 3 ml bisulfite-
treated DNA, 600 nM each primer, 200 nM Taq-
-Man probe, 5.5 mM MgCl2, 1 U platinum Taq poly-
merase, 200 mM each of deoxyguanosine triphos-
phate, and 2% Rox reference. After an initial de-
naturation step at 95°C for two minutes, 40 cycles
of 15 seconds at 95°C and one minute at 60°C for
annealing and extension were run using a CFX96
Real-Time PCR Detection System (Bio-Rad, CA,
USA). Normal leukocyte DNA was methylated in
vitro with Sss I methylase (New England Biolabs,
Beverly, MA, USA) to generate completely methy-
lated DNA as a positive control. Each plate con-
tained triplicate samples, multiple water blanks, as
well as negative unmethylated controls and serial
dilutions of positive methylated control to construct the
standard curve. The internal reference gene b-actin was
used to normalize the amount of input DNA. The
primers and TaqMan probes used in the present
study were designed using Methyl Primer Express
Software v1.0 (Applied Biosystems) and presented
in Table 2. The relative methylation level of each
sample was calculated using the method described
previously [9].
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Data analysis
A positive gene methylation was defined when the
ratio was above a certain cut-off value. The relative
methylation level varied substantially among the nine
genes and the cut-off points were thus studied for each
gene individually. To determine cut-off value of each
gene, we construct receiver operating characteristic
(ROC) curves using MedCalc software (MedCalc,
Belgium). The area under the ROC curve is a mea-
sure of the ability of a continuous marker to accu-
rately classify cancerous and noncancerous tissue.
Such a curve is a plot of sensitivity vs. 100 minus speci-
ficity values associated with all dichotomous markers
that can be formed by varying the cut-off values used
to define a marker ‘positive gene methylation’. Lo-
gistic regression models were used to examine the
association between gene methylation and the clini-
copathological features of cases using the MedCalc
software (MedCalc, Belgium). First, univariate mo-
dels were examined, then multivariate models were
developed that adjusted for the most important co-
variates, including age, pack-years, histologic type, and
histologic stage.
Associations were expressed as odds ratios and
their corresponding 95% confidence intervals (CI).
Analyses were conducted to assess the association with
NSCLC for each gene separately, then for concomi-
tant hypermethylation of multiple genes. p < 0.05 was
considered to be statistically significant. All statisti-
cal analyses were performed using the SPSS statisti-
cal package v11.5 (Chicago, IL, USA).
Results
Frequent promoter hypermethylation in NSCLC
The methylation profiles of nine genes were assessed
in their promoters using Q-MSP in a cohort of NSCLC
samples, including CALCA, CDH1, DAPK1, EVX2,
IRX2, PAX6, RARb, RASSF1A, and TIMP3. As
shown in Figure 1, the overall methylation level of
each of the nine genes was higher in cancerous tis-
sues than in noncancerous lung tissues. Among them,
significant differences were found in CALCA (p <
< 0.01), CDH1 (p < 0.01), EVX2 (p < 0.01), PAX6
(p < 0.01), RARb (p < 0.01), and RASSF1A (p < 0.05).
The cut-off values for each gene were calculated us-
ing ROC curves to differentiate NSCLC from non-
cancerous lung tissues, respectively, and determine
diagnostic sensitivity and specificity. As shown in Figu-
re 2, with more weight toward specificity than sensi-
tivity, 100% diagnostic specificity was obtained for all
of these genes. The sensitivity of each individual gene
was 69.2% for CALCA, 45.8% for CDH1, 84.1% for
DAPK1, 63.6% for EVX2, 52.3% for IRX2, 75.7%
for PAX6, 54.2% for RARb, 72.9% for RASSF1A,
and 44.9% for TIMP3.
Association of promoter hypermethylation
with clinicopathologic features of NSCLC
Among all clinicopathologic features, methylation
levels varied substantially by histologic type (Table 3).
Methylation level of most genes was higher in SCC
than in ADC, including CALCA, CDH1, DAPK1,
EVX2, IRX2, RARb, and TIMP3, particularly in
DAPK1 (p < 0.01) and TIMP3 (p < 0.01) (Table 3).
Conversely, methylation level of RASSF1A was much
higher in ADC than in SCC (Table 3), although no
significant difference was observed (p = 0.08). There
was no significant association between gene methyla-
tion and age (Table 3). Among all hypermethylated
genes, methylation level of CALCA was only found
to be significantly associated with smoking history
(p < 0.05) (Table 3). Methylation level of all of these
genes was not significantly associated with invasion
and adhesion (Table 3). Table 3 also shows that there
was a significantly lower methylation level of
RASSF1A in the lymph node metastasis group than
in the nonmetastasis group (p < 0.05). Moreover,
methylation level of CALCA was found to be signifi-
cantly associated with histologic stage (p < 0.05) (Ta-
ble 3). However, no association was found between
promoter hypermethylation and other clinocopatho-
logic features, including gender, quantity of cigarette
smoking (pack-years), tumor size, or pleural inden-
tation (data not shown).
In univariate analyses, hypermethylation of most
genes was more frequent in SCC compared to ADC,
particularly in CDH1 (OR = 2.63, 95% CI = 1.05–
–6.60), DAPK1 (OR = 6.64, 95% CI = 1.85–23.8),
IRX2 (OR = 2.89, 95% CI = 1.17–7.13), and TIMP3
(OR = 2.51, 95% CI = 1.01–6.21) (Table 4). Con-
versely, hypermethylation of RASSF1A was signifi-
cantly frequent in ADC (OR = 0.31, 95% CI = 0.09–
–0.99) in the present study (Table 4). In addition, hy-
permethylation of CALCA (OR = 2.13, 95% CI =
= 1.01–4.47) and TIMP3 (OR = 1.88, 95% CI = 1.01–
–3.49) was significantly associated with histologic stage
(Table 4). Of note, hypermethylation of RARb was
negatively associated with smoking history (OR =
=  0.50, 95% CI = 0.20–1.23), quantity of cigarette
smoking (OR = 0.60, 95% CI = 0.36–1.01) and pleu-
ral indentation (OR = 0.41, 95% CI = 0.15–1.11) in
NSCLC, although no statistical significance was no-
ted (Table 4). Additionally, hypermethylation of
RASSF1A (OR = 0.47, 95% CI = 0.24–0.90) was sig-
nificantly negatively associated with histologic stage
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Figure 1. Distribution patterns of promoter hypermethylation of the nine genes in NSCLC. Quantitative methylation-
-specific PCR (Q-MSP) assay was performed as described in Material and methods. The relative methylation level
(on Y axis) is represented by ratios of candidate gene/b-actin × 1,000, except for EVX2 and PAX6/b-actin × 100. Horizon-
tal lines indicate a 95% normal confidence interval for the sample mean. T — cancerous tissues; N — noncancerous lung
tissues. *p < 0.05; **p < 0.01; ***p < 0.001
(Table 4). Similarly, hypermethylation of RASSF1A
was also negatively associated with smoking history
(OR = 0.58, 95% CI = 0.20–1.62), lymph node me-
tastasis (OR = 0.47, 95% CI = 0.18–1.25), and inva-
sion or adhesion (OR = 0.44, 95% CI = 0.17–1.11),
respectively, although these associations did not reach
statistical difference (Table 4). In order to assess the
independent associations between gene methylation
and age, pack-years, histologic type, and histologic
stage, we conducted multiple multivariable logistic
regressions (Table 5).
In multivariable analyses adjusting for the poten-
tial false discovery rate associated with multiple com-
parisons (nine different models), hypermethylation
of CDH1 (OR = 3.14, 95% CI = 1.14–8.65), DAPK1
(OR = 8.07, 95% CI = 1.75–37.2), and IRX2 (OR
= 3.54, 95% CI = 1.29–9.73) remained associated
with histologic type, which was significantly more
likely in SCC than in ADC (Table 5). However, af-
ter adjustment, there were no significant differen-
ces between hypermethylation of RASSF1A and
TIMP3 and histologic type (Table 5). Interestingly,
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Figure 2. Receiver operating characteristic (ROC) curves for the nine genes in NSCLC. Complete DNA methylation data
from all cancerous and noncancerous lung tissues were used for the analyses. The ROC curves plot sensitivity vs. 100%-
-specificity. The cut-off values for each of nine genes were determined based on ROC curves individually
hypermethylation of RARb remained negatively as-
sociated with quantity of cigarette smoking after mul-
tivariable adjustment, and a statistical difference was
noted (OR = 0.58, 95% CI = 0.34–0.99) (Table 5).
Moreover, multivariable analyses indicated that no
significant differences were found between hyper-
methylation of CALCA and TIMP3 and histologic
stage (Table 5). However, hypermethylation of
RASSF1A (OR = 0.55, 95% CI = 0.27–1.10) re-
mained negatively associated with histologic type
(Table 5), although this association did not reach
statistical difference.
Concomitant hypermethylation of multiple genes
and their associations with clinocopathologic
features in NSCLC
Field cancerization effects in NSCLC will probably
dictate the development of a gene panel for early de-
tection of NSCLC that focuses on assessing the preva-
lence for promoter hypermethylation of multiple genes
in individual specimens. In the present study, we iden-
tified a panel of the nine hypermethylated genes with
100% diagnostic specificity in NSCLC, and further
analyzed methylation status of these genes in indivi-
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Table 5. Promoter hypermethylation of individual genes in NSCLC — multivariable models assessing age, pack-years,
histologic type, and histologic stage (OR† and 95% CI)
Genes Age1 Pack-years2 SSC vs. ADC Histologic stage3
CALCA 0.97 (0.59–1.59) 0.76 (0.42–1.35) 1.87 (0.70–5.01) 1.94 (0.87–4.31)
CDH1 0.81 (0.51–1.29) 0.81 (0.47–1.39) 3.14 (1.14–8.65)* 0.87 (0.45–1.65)
DAPK1 1.10 (0.55–2.20) 1.53 (0.67–3.48) 8.07 (1.75–37.2)* 0.60 (0.20–1.80)
EVX2 1.16 (0.71–1.88) 0.71 (0.40–1.25) 2.14 (0.80–5.72) 1.35 (0.66–2.77)
IRX2 0.74 (0.46–1.18) 0.80 (0.47–1.38) 3.54 (1.29–9.73)* 0.86 (0.44–1.65)
PAX6 1.24 (0.72–2.13) 0.88 (0.47–1.65) 0.80 (0.26–2.42) 1.93 (0.82–4.50)
RARb 1.18 (0.74–1.88) 0.58 (0.34–0.99)* 1.11 (0.42–2.90) 0.99 (0.52–1.90)
RASSF1A 0.96 (0.57–1.65) 0.81 (0.44–1.50) 0.44 (0.13–1.54) 0.55 (0.27–1.10)
TIMP3 1.10 (0.69–1.77) 1.13 (0.66–1.93) 1.89 (0.70–5.05) 1.63 (0.85–3.13)
†OR — odds ratio with 95% confidence interval, adjusted for multiple comparisons; 1Age (per 10 years); 2Pack-years (0; > 0 and < 40; ≥ 40);
3Histologic stage (I; II; III); *Significant at p < 0.05
Table 4. Promoter hypermethylation of individual genes in NSCLC — univariate associations with clinicopathological
features (OR† and 95% CI)
Genes Male vs. female Age (per 10 years) Smoking history Pack-years1 SSC vs. ADC
CALCA 0.73 (0.28–1.90) 0.94 (0.58–1.52) 1.43 (0.57–3.57) 0.88 (0.51–1.51) 2.21 (0.89–5.47)
CDH1 2.13 (0.86–5.22) 0.83 (0.53–1.30) 1.41 (0.59–3.39) 0.91 (0.55–1.50) 2.63 (1.05–6.60)*
DAPK1 1.45 (0.43–4.87) 1.16 (0.60–2.24) 2.11 (0.64–6.92) 1.83 (0.84–3.98) 6.64 (1.85–23.8)*
EVX2 0.94 (0.38–2.33) 1.12 (0.70–1.80) 1.16 (0.47–2.85) 0.82 (0.48–1.41) 2.16 (0.89–5.29)
IRX2 1.29 (0.54–3.06) 0.76 (0.48–1.19) 1.06 (0.45–2.52) 0.91 (0.55–1.50) 2.89 (1.17–7.13)*
PAX6 1.04 (0.37–2.88) 1.19 (0.70–2.03) 0.78 (0.27–2.25) 0.93 (0.51–1.69) 1.04 (0.37–2.88)
RARb 0.75 (0.31–1.81) 1.13 (0.72–1.77) 0.50 (0.20–1.23) 0.60 (0.36–1.01) 0.92 (0.39–2.19)
RASSF1A 0.75 (0.28–2.05) 0.98 (0.59–1.62) 0.58 (0.20–1.62) 0.73 (0.41–1.30) 0.31 (0.09–0.99)*
TIMP3 1.09 (0.46–2.60) 1.09 (0.70–1.71) 1.09 (0.46–2.60) 1.27 (0.76–2.11) 2.51 (1.01–6.21)*
Genes Tumor size2 Lymph node metastasis Pleural indentation Invasion or adhesion Histologic stage3
CALCA 1.01 (0.55–1.88) 1.74 (0.62–4.91) 1.18 (0.41–3.41) 2.44 (0.88–6.79) 2.13 (1.01–4.47)*
CDH1 1.20 (0.67–2.13) 1.02 (0.41–2.51) 1.79 (0.67–4.76) 0.96 (0.41–2.27) 1.11 (0.62–2.02)
DAPK1 1.81 (0.72–4.54) 5.17 (0.64–42.0) 1.63 (0.33–8.02) 1.70 (0.43–6.67) 1.24 (0.50–3.08)
EVX2 0.79 (0.43–1.43) 1.25 (0.48–3.28) 0.81 (0.30–2.21) 1.43 (0.57–3.61) 1.51 (0.78–2.93)
IRX2 1.57 (0.88–2.83) 1.17 (0.47–2.88) 1.37 (0.52–3.63) 0.86 (0.36–2.01) 1.14 (0.63–2.07)
PAX6 0.78 (0.40–1.54) 0.74 (0.26–2.09) 2.04 (0.54–7.69) 1.84 (0.61–5.56) 1.76 (0.79–3.93)
RARb 0.78 (0.44–1.39) 1.43 (0.57–3.58) 0.41 (0.15–1.11) 1.44 (0.60–3.45) 0.94 (0.52–1.70)
RASSF1A 1.12 (0.59–2.14) 0.47 (0.18–1.25) 1.76 (0.53–5.84) 0.44 (0.17–1.11) 0.47 (0.24–0.90)*
TIMP3 1.67 (0.92–3.01) 2.05 (0.82–5.10) 1.16 (0.44–3.05) 0.69 (0.29–1.66) 1.88 (1.01–3.49)*
†OR — odds ratio with 95% confidence interval; *Significant at p < 0.05; 1Pack-years (0; > 0 and < 40; ≥ 40); 2Tumor size (>1 and £ 3; > 3
and £ 5; > 5); 3Histologic stage (I, II, III)
duals. The results showed that the prevalence of con-
comitant methylation of five or more genes, six or more
genes, seven or more genes, and eight or more genes
in NSCLC were 65/96 (67.7%), 48/96 (50%), 37/96
(38.5%), and 23/96 (24%), respectively. In addition,
there was a significantly increased frequency for con-
comitant hypermethylation of multiple genes in SCC
compared to ADC (data not shown).
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Discussion
Epigenetic gene silencing is a molecular mechanism
of silencing a gene by methylating its promoter re-
gion. Epigenetic silencing is involved in initiation and
progression of human cancer [10], including NSCLC
[11, 12]. The aim of this study is to identify a panel of
hypermethylated genes with high sensitivity and speci-
ficity for early detection of NSCLC and explore their
associations with clinocopathologic features of cases
using a Q-MSP approach. Hypermethylation of most
of these genes, as a mechanism for their silencing,
has been frequently reported in NSCLC [13–17].
Moreover, this study also involved three new methy-
lation markers, EVX2, IRX2, and PAX6, which were
highly specific for tumor-associated methylation, and
little or no methylation was found in non-malignant
lung tissue [18]. Our data showed that there were sig-
nificant differences in the methylation level between
cancerous and noncancerous lung tissues from six of
nine genes, including CALCA, CDH1, EVX2, PAX6,
RARb, and RASSF1A (Figure 1). It is worth noting
that 100% diagnostic specificity, and excellent sensi-
tivity, ranging from 44.9% to 84.1%, was obtained for
each of the nine genes (Figure 2), suggesting that these
methylation markers play a role in tumor develop-
ment and make them excellent candidates for early
diagnosis and prognostic evaluation of NSCLC.
Our study found that promoter hypermethylation
of most of the genes was strongly associated with his-
tologic type. Among them, a number of genes were
more frequently methylated in SCC than in ADC (Ta-
bles 3 and 4). Unlike what was observed in the present
study, previous studies have indicated that a number
of genes were more frequently methylated in ADC,
not in SSC [17, 19, 20], which is new to the literature.
Of note, similar to a previous study [21], the present
study showed that hypermethylation of RASSF1A was
negatively associated with smoking history, lymph
node metastasis, invasion or adhesion. Importantly,
RASSF1A was more frequently methylated in the
early tumor stage (Table 4), suggesting that RASSF1A
hypermethylation may be an early molecular event in
the development of a lung tumor.
Our study did not find a significant association
between hypermethylation of most of the genes and
smoking history in NSCLC, except for CALCA gene.
This accords with most studies [22–25], although to-
bacco smoking plays a central role in the develop-
ment of lung cancer. However, several studies, as well
as the present study, have reported aberrant methy-
lation of some tumor-related genes was associated
with tobacco smoking in lung cancer [19, 23, 26], such
as p16 and CALCA genes. It is possible that smo-
king-associated lung cancer is a complex disease which
involves many unique genetic and epigenetic altera-
tions. Thus, a better understanding of the molecular
mechanisms underlying this disease would undoubt-
edly improve the clinical outcomes of patients with
NSCLC.
A very recent study showed that a number of im-
portant tumor-related genes are more frequently
methylated in females compared to males in NSCLC,
suggesting that certain methylation events are asso-
ciated with gender [17]. However, these differences
have not been consistently found in most of the pre-
vious studies [20, 27, 28]. Similarly, hypermethylation
of all of these genes was also not significantly associa-
ted with gender in the present study. It is possible
that the differences in the promoter hypermethyla-
tion associated with gender may be related to geo-
graphical or cultural differences, and, more impor-
tantly, differences in environmental carcinogen ex-
posure [29–31]. The discrepant results might also have
been caused by genetic differences between the study
populations [32]. Moreover, it is possible that these
differences are attributable to chance as a result of
the relatively small cohort of study subjects. Further
study with more subjects will thus be needed.
Concomitant methylation of multiple genes is com-
mon, particularly in cancerous tissues, which is strong-
ly associated with lung cancer risk [33, 34]. In the
present study, we identified a panel of the nine hy-
permethylated genes with excellent specificity and
sensitivity, which were only methylated in cancerous
tissues but not in noncancerous tissues. Among these
nine genes, concomitant methylation of five or more
genes was detected in 67.7% (65/96) of NSCLCs;
methylation of eight or more genes was also detected
in 24% (23/96) of NSCLCs, suggesting that methyla-
tion of these genes could be used as an indicator of
a widespread methylation phenotype in NSCLC. To-
day, gene methylation in biological fluids is emerging
as a biomarker that could be important for the early
detection of lung cancer and monitoring prevention
and intervention. Thus, our findings reinforce the use
of this panel of hypermethylated genes as a biomark-
er for early detection and prognostic evaluation of
lung cancer.
To sum up, we identified a panel of hypermethy-
lated genes that differentiate cancerous tissues from
noncancerous tissues, and demonstrated that promot-
er hypermethylation was strongly associated with his-
tologic type. Importantly, highly frequent concomi-
tant methylation of multiple genes was found in
NSCLC, particularly in SCC, strongly suggesting that
a methylated gene panel from sputum or plasma may
have potential in noninvasively detecting NSCLC, as
well as in evaluating the prognosis in post-operative
NSCLC patients.
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